Group 1 - Tyra Biosciences, Inc. is a clinical-stage biotechnology company focused on developing next-generation precision medicines targeting Fibroblast Growth Factor Receptor (FGFR) biology [2] - The company utilizes its in-house precision medicine platform, SNÅP, for rapid and precise drug design, predicting genetic alterations that may cause resistance to existing therapies [2] - Tyra's lead product, dabogratinib, is a potential first-in-class selective FGFR3 inhibitor designed to minimize toxicities associated with other FGFR inhibitors [2] Group 2 - Current clinical development plans for dabogratinib include studies for intermediate risk non-muscle invasive bladder cancer, pediatric achondroplasia, and potential future studies for metastatic urothelial cancer [2] - Tyra is also developing TYRA-430, an oral FGFR4/3-biased inhibitor for FGF19+/FGFR4-driven cancers, and TYRA-200, an oral FGFR1/2/3 inhibitor for metastatic intrahepatic cholangiocarcinoma [2] - The company will participate in investor events, including a virtual fireside chat on August 21, 2025, and the H.C. Wainwright 27th Annual Global Investment Conference on September 10, 2025 [1]

Company Overview - Tyra Biosciences, Inc. is a clinical-stage biotechnology company focused on developing next-generation precision medicines targeting opportunities in Fibroblast Growth Factor Receptor (FGFR) biology [1] - The company utilizes an in-house precision medicine platform called SNÅP, which enables rapid and precise drug design through iterative molecular SNÅPshots [1] - Tyra has a differentiated pipeline with three clinical-stage programs in targeted oncology and genetically defined conditions [1] Lead Product and Clinical Development - The lead product, TYRA-300, is a potential first-in-class selective FGFR3 inhibitor designed to avoid toxicities associated with FGFR1, FGFR2, and FGFR4 inhibition [1] - TYRA-300's planned clinical development includes three Phase 2 studies: SURF302 for intermediate risk non-muscle invasive bladder cancer, BEACH301 for pediatric achondroplasia, and SURF301 for metastatic urothelial cancer [1] - Other investigational products include TYRA-200, an oral FGFR1/2/3 inhibitor for metastatic intrahepatic cholangiocarcinoma, and TYRA-430, an oral FGFR4/3-biased inhibitor for FGF19+/FGFR4-driven cancers [1] Upcoming Event - Company management will participate in a virtual fireside chat as part of the UBS Biotech Management Live Call Series on July 25, 2025 [2] - The event will feature key management personnel including Todd Harris (CEO), Doug Warner (CMO), and Alan Fuhrman (CFO) [2] - The session is scheduled for 11 am ET and will be hosted by Ellie Merle, a US SMID Cap Biotechnology Analyst at UBS [2]